Narcolepsy

Sleep Disorders Medicine

Volumn , Issue , 2009, Pages 377-396

  Guilleminault, Christian ^a   Abad, Vivien C ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Camino Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872611303     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-7584-0.00027-6     Document Type: Chapter

References (177)

1. Gelineau J. De la narcolepsie. Gaz Hop (Paris) 1880, 53:626.
2. Henneberg R. Uber genuine Narkolepsie. Neurol Zb1 1916, 30:282.
3. Gelineau J. De la narcolepsie. Tessier Surgere 1881, (France).
4. Daniels L. Narcolepsy. Medicine 1934, 13:1.
5. Daly D.D., Yoss R.E. Electroencephalogram in narcolepsy. Electroencephalogr Clin Neurophysiol Suppl 1957, 9:109.
6. Yoss R.E., Daly D.D. Criteria for the diagnosis of the narcoleptic syndrome. Mayo Clin Proc 1957, 32:320.
7. Vogel G. Studies in psychophysiology of dreams. III. The dream of narcolepsy. Arch Gen Psychiatry 1960, 3:421.
8. Passouant P., Schwab R.S., Cadilhac J., et al. Narcolepsie-cataplexie: etude du sommeil de nuit et du sommeil de jour. Rev Neurol (Paris) 1964, 3:415.
9. Rechtschaffen A., Wolpert E.A., Dement W.C., et al. Nocturnal sleep of narcoleptics. Electroencephalogr Clin Neurophysiol 1963, 15:599.
10. Narcolepsy 1975, 1. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
11. Juji T., Satake M., Honda Y., Doi Y. HLA antigens in Japanese patients with narcolepsy: all the patients were DR2 positive. Tissue Antigens 1984, 24:316.
12. Honda Y., Asake A., Tanaka Y., Juji T. Discrimination of narcolepsy by using genetic markers and HLA. Sleep Res 1983, 12:254.
13. Mignot E., Hayduk R., Black J., et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997, 20:1012.
14. Pelin Z., Guilleminault C., Risch N., et al. HLA DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 1998, 51:96.
15. Nishino S., Ripley B., Overeem S., et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39.
16. Melberg A., Ripley B., Lin L., et al. Hypocretin deficiency in familial symptomatic narcolepsy. Ann Neurol 2001, 49:136.
17. International Classification of Sleep Disorders. rev: Diagnostic and Coding Manual 2005, American Academy of Sleep Medicine, American Academy of Sleep Medicine, Chicago. 2nd ed.
18. Dement W., Rechtschaffen A., Gulevich G. The nature of the narcoleptic sleep attack. Neurology 1966, 16:18.
19. Guilleminault C., Fromherz S. Narcolepsy: diagnosis and management. Principles and Practice of Sleep Medicine 2005, 780. Elsevier Saunders, Philadelphia. M. Kryger, T. Roth, W. Dement (Eds.).
20. Guilleminault C., Wilson R.A., Dement W.C. A study on cataplexy. Arch Neurol 1974, 31:255.
21. Guilleminault C., Gelb M. Clinical aspects and features of cataplexy. Adv Neurol 1995, 67:65.
22. Anic-Labat S., Guilleminault C., Kraemer H.C., et al. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999, 22:77.
23. Eisensehr I., Linke R., Tatsch K., et al. Alteration of the striatal dopaminergic system in human narcolepsy. Neurology 2003, 60:1817.
24. Yeon Joo E., Hong S.B., Tae W.S., et al. Cerebral perfusion abnormality in narcolepsy with cataplexy. Neuroimage 2005, 28:410.
25. Chabas D., Habert M.O., Maksud P., et al. Functional imaging of cataplexy during status cataplecticus. Sleep 2007, 30:153.
26. Bowling G., Richards N.G. Diagnosis and treatment of the narcolepsy syndrome. Cleveland Clin Q 1961, 28:38.
27. Kales A., Cadieux R.J., Soldatos C.R., et al. Narcolepsy-cataplexy I: clinical and electrophysiologic characteristics. Arch Neurol 1982, 39:164.
28. Parkes J.D., Chen S.Y., Clift S.J., et al. The clinical diagnosis of the narcoleptic syndrome. J Sleep Res 1998, 7:41.
29. Montplaisir J., Billiard M., Takahashi S., et al. Twenty-four hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol Psychiatry 1978, 13:73.
30. Zorick F., Piccione P., Hartse K.M., et al. Disturbed nocturnal sleep in narcolepsy. Sleep Res 1980, 9:223.
31. Baker T.L., Guilleminault C., Nino-Murcia G., Dement W.C. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep 1986, 9:232.
32. Baker T., Leder R., Colbert M., et al. Periodic leg movements during NREM and REM sleep in narcolepsy syndrome. Sleep Res 1987, 16:302.
33. Schenk C.H., Mahowald M.W. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behaviour disorder. Ann Neurol 1992, 32:3.
34. Abad V.C., Guilleminault C. Review of rapid eye movement behavior sleep disorders. Curr Neurol Neurosci Rep 2004, 4:157.
35. Dauvilliers Y., Pennestri M.H., Petit D., et al. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res 2007, 16:333.
36. Mattarozzi K., Bellucci C., Campi C., et al. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy. Sleep Med 2008, 9:425-433.
37. Dauvilliers Y., Rompré S., Gagnon J.F., et al. REM sleep characteristics in narcolepsy and REM sleep behavior disorder. Sleep 2007, 30:844.
38. Guilleminault C., Anders T.F. The pathophysiology of sleep disorders in pediatrics Part II. Sleep disorders in children. Adv Pediatr 1976, 22:151.
39. Guilleminault C., Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 1998, 43:135.
40. Guilleminault C., Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2000, 2:1.
41. Wise M.S., Lynch J. Narcolepsy in children. Semin Pediatr Neurol 2001, 8:198.
42. Stores G. Recognition and management of narcolepsy. Arch Dis Child 1999, 81:519.
43. Macleod S., Ferrie C., Zuberi S.M. Symptoms of narcolepsy in children misinterpreted as epilepsy. Epileptic Disord 2005, 7:13.
44. Guilleminault C., Zvonkina V., Tantrakul V., Kim J.H. Advances in narcolepsy syndrome and challenges in the pediatric population. Sleep Med Clin 2007, 2:397.
45. Huang Y.S., Tafti M., Guilleminault C. Daytime sleepiness with and without cataplexy in Chinese-Taiwanese patients. Sleep Med 2006, 7:454.
46. Billiard M., Besset A., Cadilhac J. The clinical and polygraphic development of narcolepsy. Sleep/Wake Disorders 1983, 187. Natural History, Epidemiology, and Long-Term Evolution, New York: Raven. C. Guilleminault, E. Lugaresi (Eds.).
47. Daniels E., King M.A., Smith I.E., Shneerson J.M. Health-related quality of life in narcolepsy. J Sleep Res 2001, 10:75.
48. Broughton R., Ghanem Q., Hishikawa Y., et al. Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can J Neurol Sci 1981, 8:299.
49. Vignatelli L., D'Alessandro R., Mosconi P., et al. Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey. Sleep Med 2004, 5:467.
50. Reimer M.A., Flemons W.W. Quality of life in sleep disorders. Sleep Med Rev 2003, 7:335.
51. Kavey N.B. Psychosocial aspects of narcolepsy in children and adolescents. Psychosocial Aspects of Narcolepsy 1992, 91. Haworth, New York. M. Goswami, C.P. Pollak, F.L. Cohen (Eds.).
52. Aldrich M.S. Automobile accidents in patients with sleep disorders. Sleep 1989, 12:487.
53. Findley L., Unverzagt M., Guchu R., et al. Vigilance and automobile accidents in patients with sleep apnoea or narcolepsy. Chest 1995, 108:619.
54. Kotterba S., Mueller N., Leidag M., et al. Comparison of driving simulator performance and neuropsychological testing in narcolepsy. Clin Neurol Neurosurg 2004, 106:275.
55. Broughton R., Ghanem Q. The impact of compound narcolepsy on the life of the patient. Narcolepsy 1976, 201. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
56. Hoddes E., Dement W.C., Zarcone V. The development and use of the Stanford Sleepiness Scale (SSS). Psychophysiology 1972, 9:150.
57. Carskadon M., Dement W.C., Mitler M.M., et al. Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness. Sleep 1986, 9:519.
58. Littner M., Kushida C., Wise M., et al. Practice parameters for clinical use of the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test. Sleep 2005, 28:113.
59. Sangal R.B., Thomas L., Mitler M.M. Maintenance of Wakefulness Test and Multiple Sleep Latency Test: measurement of different abilities in patients with sleep disorders. Chest 1992, 101:898.
60. Palm L., Persson E., Elmqvist D., Blennow G. Sleep and wakefulness in normal preadolescent children. Sleep 1989, 12:299.
61. Carskadon M.A., Harvey K., Duke P., et al. Pubertal changes in daytime sleepiness. Sleep 1980, 2:453.
62. Levine B., Roehrs T., Zorick F., Roth T. Daytime sleepiness in young adults. Sleep 1988, 11:39.
63. Carskadon M.A., Brown E.D., Dement W.C. Sleep fragmentation in the elderly: relationship to daytime sleep tendency. Neurobiol Aging 1982, 3:321.
64. Dauvilliers Y., Gosselin A., Paquet J., et al. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 2004, 62:46.
65. Arand D., Bonnet M., Hurwitz T., et al. The clinical use of the MSLT and MWT. Sleep 2005, 28:123.
66. Aldrich M.S., Chervin R.D., Malow B.A. Value of the Multiple Sleep Latency Test (MSLT) for the diagnosis of narcolepsy. Sleep 1997, 20:620.
67. Bishop C., Rosenthal L., Helmus T., et al. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. Sleep 1996, 19:727.
68. Chervin R.D., Aldrich M.S. Sleep onset REM periods during multiple sleep latency tests in patients evaluated for sleep apnea. Am J Crit Care Med 2000, 161(2 Pt I):426.
69. Goncalves M.A., Guilleminault C., Ramos E., et al. Erectile dysfunction, obstructive sleep apnea syndrome and nasal CPAP treatment. Sleep Med 2005, 6:333.
70. Guilleminault C., Partinen M., Quera-Salva M.A., et al. Determinants of daytime sleepiness in obstructive sleep apnea. Chest 1988, 94:32.
71. Mitler M.M., Gujavarty K.S., Browman C.P. Maintenance of Wakefulness Test: a polysomnographic technique for evaluation of treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neurophysiol 1982, 53:658.
72. Doghramji K., Mitler M.M., Sangal R.B., et al. A normative study of the maintenance of Wakefulness Test (MWT). Electroencephalogr Clin Neurophysiol 1997, 103:554.
73. Browman C.P., Gujavarty K.S., Sampson M.G., et al. REM episodes during the Maintenance of Wakefulness Test in patients with sleep apnea syndrome and patients with narcolepsy. Sleep 1983, 6:23.
74. Oka Y., Kanbayashi T., Mezaka T., et al. Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis. J Neurol 2004, 251:885.
75. Baumann C.R., Stocker R., Imhof H.G., et al. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 2005, 65:147.
76. Dohi K., Ripley B., Fujiki N., et al. CSF hypocretin-1/orexin-A concentrations in patients with subarachnoid hemorrhage (SAH). Peptides 2005, 26:2339-2343.
77. Nevsimalova S., Vankova J., Stepanova I., et al. Hypocretin deficiency in Prader-Willi syndrome. Eur J Neurol 2005, 12:70.
78. Nishino S., Kanbayashi T., Fujiki N., et al. CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 2003, 61:823.
79. Castillo P.R., Mignot E., Woodruff B.K., Boeve B.F. Undetectable CSF hypocretin-1 in "Hashimoto's encephalopathy" associated with coma. Neurology 2004, 62:1909.
80. Guilleminault C., Mignot E., Grumet C. Family study of narcolepsy. Lancet 1989, 2:1376.
81. Mignot E., Hayduk R., Black J., et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997, 20:1012.
82. Mignot E. Narcolepsy: pharmacology, pathophysiology, and genetics. Principles and Practice of Sleep Medicine 2005, 761. Elsevier Saunders, Philadelphia. M. Kryger, T. Roth, W.C. Dement (Eds.).
83. Pollmacher R., Dalal M., Schuld A. Immunoendocrine abnormalities in narcolepsy. Sleep Med Clin 2007, 2:293.
84. Van den Hoed J., Kraemer H., Guilleminault C., et al. Disorders of excessive daytime somnolence: polygraphic and clinical data for 100 patients. Sleep 1981, 4:23.
85. Moscovitch A., Partinen M., Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology 1993, 43:55.
86. Billiard M., Seignalet J., Besset A., Cadilhac J. HLA-DR2 and narcolepsy. Sleep 1986, 9(1 Pt 2):149.
87. Partinen M., Hublin C. Epidemiology of sleep disorders. Principles and Practice of Sleep Medicine 2005, 631. Elsevier Saunders, Philadelphia. M. Kryger, T. Roth, W.C. Dement (Eds.).
88. Honda Y. Census of narcolepsy, cataplexy, and sleep life among teen-agers in Fujisawa City. Sleep Res 1979, 8:191.
89. Honda Y., Asaka A., Tanimura M., Furosho T. A genetic study of narcolepsy and excessive daytime sleepiness in 308 families with a narcolepsy of hypersomnia proband. Sleep/Wake Disorders 1983, 187. Natural History, Epidemiology, and Long-Term Evolution, New York: Raven. C. Guilleminault, E. Lugaresi (Eds.).
90. Tashiro T., Kanbayashi T., Iijima S., Hishikawa Y. An epidemiological study on the prevalence of narcolepsy in Japanese. J Sleep Res 1992, 1(Suppl 1):228.
91. Ohayon M.M., Priest J.H., Zulley J., et al. Prevalence of narcolepsy, symptomatology and diagnosis in the European general population. Neurology 2002, 58:1826.
92. Dement W., Zarcone V., Varner V., et al. The prevalence of narcolepsy. Sleep Res 1972, 1:148.
93. Dement W., Carskadon M., Ley R. The prevalence of narcolepsy: II. Sleep Res 1973, 2:147.
94. Silber M.H., Krahn L.E., Olson E.J., Pankratz V.S. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002, 25:197.
95. Hublin C., Partinen M., Kaprio J., et al. Epidemiology of narcolepsy. Sleep 1994, 17(8 Suppl):S7.
96. Wilner A., Steinman L., Lavie P., et al. Narcolepsy-cataplexy in Israeli Jews is associated exclusively with the HLA DR2 haplotype: a study at the serological and genomic level. Hum Immunol 1988, 21:15.
97. Dauvilliers Y., Montplaisir J., Molinari N., et al. Age of onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001, 57:2029.
98. Dauvilliers Y., Carlander B., Molinari N., et al. Month of birth as a risk factor for narcolepsy. Sleep 2003, 26:663.
99. Longstreth W.T., Koepsell T.D., Ton T.G., et al. The epidemiology of narcolepsy. Sleep 2007, 30:13.
100. Dahmen N., Bierbrauer J., Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 2001, 251:85.
101. Kok S.W., Overeem S., Visscher T.L., et al. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 2003, 11:1147.
102. Matsuki K., Honda Y., Satake M., et al. HLA in narcolepsy in Japan. HLA in Narcolepsy 1988, 58. Springer, Berlin. Y. Honda, T. Juji (Eds.).
103. Langdon N., Welsh K.I., van Dam M., et al. Genetic markers in narcolepsy. Lancet 1984, 2:1178.
104. Mignot E., Lin L., Rogers W., et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001, 68:686.
105. Rogers A.E., Meehan C., Guilleminault C., et al. HLA DR15(DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997, 48:1550-1556.
106. Mignot E., Kimura A., Latterman A., et al. Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic subjects with cataplexy. Tissue Antigens 1997, 49:329.
107. Mignot E., Lin X., Arrigoni J., et al. DQB1*0602 and DQA1*0602 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994, 17(8 Suppl):S60.
108. Mignot E., Lin X., Hesla P.E., et al. A novel HLA DR17,DQ1 (DQA1-0102/DQB1-0602 positive) haplotype predisposing to narcolepsy in Caucasians. Sleep 1993, 16:764.
109. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998, 50(2 Suppl 1):S16.
110. Kessler S., Guilleminault C., Dement W.C. A family study of 50 REM narcoleptics. Arch Neurol Scand 1974, 50:503.
111. Montplaisir J., Poirier G. HLA in narcolepsy in Canada. HLA in Narcolepsy 1988, 97. Springer, Berlin. Y. Honda, T. Juji (Eds.).
112. Mueller-Eckhardt G., Meier-Ewert K., Schendel D.J., et al. HLA and narcolepsy in a German population. Tissue Antigens 1986, 28:163.
113. Matsuki K., Grumet F.C., Lin X., et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 1992, 339:1052.
114. Singh S.M., George C.F., Kryger M.H., Jung J.H. Genetic heterogeneity in narcolepsy. Lancet 1990, 335:726.
115. Honda M., Honda Y., Uchida S., et al. Monozygotic twins incompletely concordant for narcolepsy. Biol Psychiatry 2001, 49:943.
116. Lankford D.A., Wellman J.J., O'Hara C. Posttraumatic narcolepsy in mild to moderate closed head injury. Sleep 1994, 17(8 Suppl):S25.
117. Orellana C., Villemin E., Tafti M., et al. Life events in the year preceding the onset of narcolepsy. Sleep 1994, 17(8 Suppl):S50.
118. Nishino S., Mignot E. Narcolepsy. Handbook of Clinical Neurophysiology 2005, Vol 6:155. Elsevier, Philadelphia. C. Guilleminault (Ed.).
119. Hohjoh H., Nakayama T., Ohashi J., et al. Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy. Tissue Antigens 1999, 54:138.
120. Hohjoh H., Terada N., Miki T., et al. Haplotype analyses with the human leucocyte antigen and tumour necrosis factor-alpha genes in narcolepsy families. Psychiatry Clin Neurosci 2001, 55:37.
121. Wieczorek S., Gencik M., Rujescu D., et al. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 2003, 61:437.
122. Nakayama J., Miura M., Honda M., et al. Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. Genomics 2000, 65:84.
123. Dauvilliers Y., Neidhart E., Lecendreux M., et al. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001, 6:367.
124. Dauvilliers Y., Neidhart E., Billiard M., Tafti M. Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. Pharmacogenomics J 2002, 2:65.
125. Nishino S., Okura M., Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms [Review]. Sleep Med Rev 2000, 4:57.
126. Ripley B., Overeem S., Fujiki N., et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253.
127. Mignot E., Lammers G.J., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553.
128. Thannickal T.C., Moore R.Y., Nienhuis R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469.
129. Thannickal T.C., Siegel J.M., Nienhuis R., Moore R.Y. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003, 13:340.
130. Black J.L., Krahn L.E., Pankratz V.S., Silber M. Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602. Sleep 2002, 25:719.
131. Overeem S., Geleijns K., Garssen M.P., et al. Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. Neurosci Lett 2003, 341:13.
132. Black J.L., Silber M.H., Krahn L.E., et al. Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry 2005, 58:504.
133. Lecendreux M., Maret S., Bassetti C., et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003, 12:347.
134. Dauvilliers Y., Carlander B., Rivier F., et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004, 56:905.
135. Chen W., Black J.E., Mignot E. Idiopathic narcolepsy-cataplexy responsive to plasmapheresis [Abstract]. Sleep 2005, 28(Abstr Suppl):A223.
136. Hecht M., Ling L., Kushida C., et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003, 26:809.
137. Littner M., Johnson S., McCall W.M., et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001, 24:451. Standards of Practice Committee.
138. Morgenthaler T., Kapur V., Brown T., et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007, 30:1705.
139. Wise M., Arand D., Auger R., et al. Treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007, 30:1712.
140. Lammers G.J., Arends J., Declerck A.C., et al. Ritanserin, a 5-HT2 receptor blocker, as add-on treatment in narcolepsy. Sleep 1991, 14:130.
141. Mayer G. Ritanserin improves sleep quality in narcolepsy. Pharmacopsychiatry 2003, 36:150.
142. Scammell T. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003, 53:154.
143. Mitler M.M., Hajdukovic R.M. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991, 14:218.
144. Mitler M.M., Aldrich M., Koob G., Zarcone V. Narcolepsy and its treatment with stimulants. Sleep 1994, 17:352.
145. Parkes J.D., Schachter M. Mazindol in the treatment of narcolepsy. Acta Neurol Scand 1979, 60:250.
146. Iijima S., Sugita Y., Teshima Y., Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 1986, 9(1 Pt 2):265.
147. Scammell T.E., Estabrooke I.V., McCarthy M.T., et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000, 20:8620.
148. Mignot E., Nishino S., Guilleminault C., Dement W.C. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994, 15:436.
149. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsyUS Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998, 43:88.
150. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsyUS Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000, 54:1166.
151. Schwartz J.R., Feldman N.T., Bogan R.K., et al. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 2003, 26:252.
152. Schwartz J.R., Nelson M.T., Schwartz E.R., Hughes R.J. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol 2004, 27:152.
153. Ivanenko A., Tauman R., Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003, 4:579.
154. Schwartz J.R., Feldman N.T., Fry J.M., Harsh J. Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Sleep Med 2003, 4:43.
155. Harsh J.R., Hayduk R., Rosenberg R., et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006, 22:761.
156. Black J., Houghton W.C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006, 29:939.
157. Hublin C., Partinen M., Heinonen E.H., et al. Selegiline in the treatment of narcolepsy. Neurology 1994, 44:2095.
158. Mayer G., Ewert Meier K., Hephata K. Selegeline hydrochloride treatment in narcolepsy: a double-blind, placebo-controlled study. Clin Neuropharmacol 1995, 18:306.
159. Larrosa O., de la Llave Y., Bario S., et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 2001, 24:282.
160. Evidenced based guidelines for the UKs with graded recommendations Available at. http://www.sleeping.org.uk/news/documents/Guidelines.pdf.
161. Challamel M.J., Mazzola M.E., Nevsimalova S., et al. Narcolepsy in children. Sleep 1994, 17:S17.
162. Philippart M., Engel J., Zimmerman E.G. Gelastic cataplexy in Niemann-Pick disease group C and related variants without generalized sphingomyelinase deficiency. Ann Neurol 1983, 14:492.
163. Kanbayashi T., Abe M., Fujimoto S., et al. Hypocretin deficiency in Niemann-Pick type C with cataplexy. Neuropediatrics 2003, 34:52.
164. Vankova J., Stepanova J., Jech R., et al. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep 2003, 26:427.
165. Einhaus S.I., Stanford R.A. Craniopharyngioma. Principles and Practice of Pediatric Neurosurgery 1999, 545. Thieme, New York. A.L. Albright, I.F. Pollack, P.D. Adelson (Eds.).
166. Schwartz W.J., Stakes J.W., Hobson J.A. Transient cataplexy after removal of a craniopharyngioma. Neurology 1984, 34:1372.
167. Malik S., Boeve B.F., Krahn L.E., Silber M.H. Narcolepsy associated with other central nervous system disorders. Neurology 2001, 57:539.
168. Scammell T.E., Nishino S., Mignot E., Saper C.B. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 2001, 56:1751.
169. Arii J., Kambayashi T., Tanabe Y., et al. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology 2001, 56:1775.
170. Marcus C.L., Trescher W.H., Halbower A.C., Lutz J. Secondary narcolepsy in children with brain tumors. Sleep 2002, 25:435.
171. Landolfi J.C., Nadkarni M. Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: case study. Neurooncology 2003, 5:214.
172. Dalmau J., Graus F., Villarejo A., et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004, 127:1831.
173. Aldrich M.S., Naylor M.W. Narcolepsy associated with lesions of the diencephalon. Neurology 1989, 39:1505.
174. D'Cruz O.F., Vaughn B.V., Gold S.H., Greenwood R.S. Symptomatic cataplexy in pontomedullary lesions. Neurology 1994, 44:2189.
175. Ma T.K., Ang L.C., Mamelak M., et al. Narcolepsy secondary to 4th ventricle subependynoma. Can J Neurol Sci 1996, 23:59.
176. Stahl S.M., Layzer R.B., Aminoff M.J., et al. Continuous cataplexy in a patient with a mid-brain tumor: the limp man syndrome. Neurology 1980, 30:1115.
177. Montplaisir J., Godbout R. Nocturnal sleep of narcoleptic patients: revisited. Sleep 1986, 9:159.